MentalHealthDaily

TRD MRI Coupling Classified Depression Resistance Above 0.88 AUC

by GLOOM

A 2026 multimodal MRI study found that treatment-resistant depression had lower coordination between brain structure and brain activity than non-treatment-resistant depression in frontal, parietal, motor, and temporal regions. Machine-learning models using those structure-function coupling measures classified treatment-resistant vs. non-treatment-resistant depression with AUC values from 0.886 to 0.950 in the primary atlas analysis.1 Research Highlights TRD …

Esketamine Failed Cost-Effectiveness vs. Cheaper TRD Options at $50K/QALY

by GLOOM

Photoreal illustration of a depression-treatment decision with cost and outcome imagery, conveying healthcare-economic decision-making.

Intranasal esketamine — FDA-approved for treatment-resistant depression in 2019 — failed cost-effectiveness benchmarks against four cheaper third-line options in a 2026 Hong Kong modeling study, with incremental cost-effectiveness ratios (ICERs) of US$134,127 to US$312,750 per quality-adjusted life-year (QALY) at a US$50,000/QALY willingness-to-pay (WTP) threshold.1 Combination antidepressant therapy was the most cost-effective strategy modeled. Research Highlights …

SSRI Pharmacogenomic Testing: CYP2D6, CYP2C19, Remission

by GLOOM

A 2026 methylome-wide association study by Shen et al. found 48 CpG methylation sites tied to the quadratic CYP2C19 metabolizer-status term in 18,396 Generation Scotland participants, with 19 sites showing non-linear patterns and targeted replication in 1,238 older adults.1 That supports CYP2C19 as real biology beneath SSRI pharmacogenomics, but it does not prove universal antidepressant …

Subcallosal Cingulate DBS for Treatment-Resistant Depression

by GLOOM

A 2026 systematic review of subcallosal cingulate (SCC) functional connectivity found 28 qualifying resting-state fMRI studies in depression: 21 rTMS/iTBS studies, 4 ECT studies, 3 focused-ultrasound studies, and 0 DBS or tDCS studies.1 That number is the useful correction: SCC DBS may still be biologically plausible, but the current fMRI connectivity literature mostly explains noninvasive …

Post-Stroke Depression Tracks Serotonin-Acetylcholine Damage

by GLOOM

Photoreal illustration of stroke lesion with overlapping neurotransmitter network damage, conveying mechanism of post-stroke depression.

A 2026 two-cohort connectome study found that post-stroke depressive symptoms tracked damage to networks weighted by the serotonin transporter and vesicular acetylcholine transporter: 5-HTT damage predicted depression in Leipzig (OR 2.4, 95% CI 1.15–5.02) and Oxford (OR 2.05, 95% CI 1.03–4.09), while VAChT damage also replicated across both cohorts.1 The dopamine part of the original …

Esketamine Can Trigger Trauma Re-Experiencing in PTSD

by GLOOM

Photoreal illustration of a patient receiving nasal spray with overlay of trauma memory imagery, conveying esketamine + PTSD interaction.

A 2026 retrospective case series of 22 adults with treatment-resistant depression and comorbid PTSD found that trauma re-experiencing during intranasal esketamine disappeared over later sessions in 72.7% of patients, while 27.3% stopped esketamine because the flashbacks persisted.1 Research Highlights Flashbacks usually faded, but not always: In 16 of 22 patients (72.7%), esketamine-related trauma re-experiencing disappeared …

IV Clomipramine Shows No Clear Edge in Depression or OCD

by GLOOM

Photoreal illustration of an IV infusion bag and capsule with brain imagery, conveying parenteral vs oral antidepressant pharmacokinetics.

Parenteral clomipramine has a strong clinical myth around it: bypass the gut, raise parent-drug exposure quickly, and maybe accelerate rescue in severe depression or OCD. A 2026 systematic review found the route advantage was not clearly proven: in depression, 5 RCTs without high risk of bias did not show clear IV or IM superiority over …